RHA® Redensity With New Anesthetic Agent - Perioral Rhytids

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 30, 2019

Primary Completion Date

February 24, 2020

Study Completion Date

November 9, 2020

Conditions
AgingPain
Interventions
DEVICE

RHA® Redensity with new anesthetic agent

A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.

DEVICE

RHA® Redensity with lidocaine

A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.

Trial Locations (3)

33146

Florida, Coral Gables

60611

Chicago, Chicago

90120

California, Beverly Hills

All Listed Sponsors
lead

Teoxane SA

INDUSTRY

NCT04069585 - RHA® Redensity With New Anesthetic Agent - Perioral Rhytids | Biotech Hunter | Biotech Hunter